MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
Special Two Endowed Professorships Celebration for Goutham Narla, MD, PhD, and Analisa DiFeo, PhD
For the Cancer Center, the afternoon of Wednesday, October 29 is a special occasion. At Severance Hall Reinberger Chamber Hall, Dean Pam Davis will recognize two of our outstanding young investigators at a ceremony to be followed by a short presentation and a reception. Please join us in congratulating Analisa DiFeo and Goutham Narla on this exciting recognition.
Analisa DiFeo joined Case Western Reserve University in March 2012 with a primary appointment as Assistant Professor of Oncology in the Cancer Center. She completed her doctoral research at Mount Sinai School of Medicine in New York where she played a central role in defining alternative splicing of the KLF6 gene family as a key regulator in ovarian cancer. She is an accomplished young investigator, with 38 peer-reviewed publications, including two in the Journal of Clinical Investigation, and a 2014 senior author publication in Nature Communications.
Analisa's work focuses on model systems for the biology and treatment of ovarian cancer. She is developing drug resistance modulation, miRNA markers of advanced disease, PDX models, and a robust tumor bank leading to collaborations across the Cancer Center. Analisa has assembled a multidisciplinary group of dedicated translational research scientists, gynecologic oncologists, clinical fellows, pathologists, informatics scientists, and biostatisticians focused on understanding the molecular defects associated with ovarian cancer initiation, progression and chemoresistance. She was also the recipient of the Liz Tilberis Scholars Award from the Ovarian Cancer Research Fund, a pilot award from the Congressionally Directed Medical Research Programs (CDMRP) in 2011, and a Mary Kay Foundation Grant.
This Wednesday, Analisa will be recognized as the Norma C. and Albert I. Geller Designated Professor of Ovarian Cancer Research at CWRU School of Medicine. The Geller family will be in attendance, providing immediate attention to their interest in advancing the science of ovarian cancer biology leading to improved diagnosis and treatment for this disease.
Goutham Narla also joined CWRU in 2012. Afterall, interviewing for positions as a couple, Goutham and Analisa became convinced that CWRU, the Institute for Transformative Medicine, and the Cancer Center were the best places for them to pursue their careers.
Goutham will receive recognition as the James T. Pardee-Carl A. Gerstacker Professor of Cancer Research at CWRU School of Medicine. This chair is designed to advance the careers of newly recruited faculty conducting cancer research, and we could not have chosen better. Trained in Medicine and Genetics, Goutham is pursuing the complexity of FoxO1 and Krupl proteins, while at the same time also developing anticancer agents which inhibit the phosphatase, Pp2a. His accomplishments focused on targeting Pp2a for inhibitors have been remarkable. He first conceived of this approach less than two years ago and already has lead compounds that are likely to enter preclinical evaluation this year. Given the fundamental role of phosphatases in cancer, it is perhaps not surprising that his efforts have identified a number of very promising agents and clinical applications in hard to treat cancers. He has 48 peer-reviewed publications in journals like Science, Science Translational Medicine, Nature Genetics, Nature Communications, Oncogene, and The Journal of Clinical Investigation, and is already establishing himself as an internationally recognized cancer investigator.
CASE CCC IN THE NEWS
University Hospitals Selects GenomOncology's GO Clinical Workbench to Launch their first NGS-based Cancer Diagnostic Test
PR Newswire - Oct 27, 2014
GenomOncology today announced that University Hospitals (UH) Case Medical Center and UH Seidman Cancer Center (Cleveland, Ohio) have selected the company's GO Clinical Workbench™ to launch a clinical cancer product. UH will leverage the GO Clinical Workbench for workflow management from raw sequencing data through delivery of an actionable clinical report for oncologists..."Cancer research not only advances cancer treatment, it also provides a source of hope and help to patients for whom other treatments have failed," said Joseph Willis, MD, Division Chief, Clinical Pathology at UH Case Medical Center. "Coupling our research efforts with the powerful analytics provided by the GO Clinical Workbench will allow us to quickly translate scientific findings into the highest quality patient care."
"Miracles Happen" Breast-cancer-fighting Benefit Set for Friday, Nov. 14th: Shaker Traces
The Plain Dealer - Oct 24, 2014
On Friday evening, Nov. 14, the seventh annual Miracles Happen Gala, an event that supports advanced breast cancer research, will take place at Shaker Heights Country Club. The gala goes to support the Miracle Fund, considered one of the first of its kind that focuses exclusively on advanced breast cancer. Established in memory of Diana Hyland of Shaker Heights, who died of metastatic breast cancer in 2008, the fund has raised nearly $4 million since its inception. This year's get-together will pay tribute to Chip Corlett and Kate Caplan, two Miracle Fund founders and fundraisers who died of cancer earlier in 2014. Proceeds from the fund go to University Hospitals Seidman Cancer Center for its efforts to devise new theories, trials and treatments aimed at managing the disease. "The Miracle Fund," Lyndsay Harris, MD, the Diana Hyland Chair for Breast Cancer at University Hospitals, said, "is a truly inspiring community endeavor that facilitates novel and highly innovative research which will unravel the molecular basis for how recurrent breast cancers arise."
Potential Lung Cancer Blood Biomarker Found
Medical News Today- Oct 22, 2104
Researchers at the Cleveland Clinic in Ohio found that patients with stage I to stage III non-small cell lung cancer – by far the most common form of the disease – have different profiles of metabolites in their blood, compared with patients who have the same risk but no disease. Metabolites are small molecules produced from digestion and other chemical processes in the body. Individual metabolites have been used as markers of disease for years. For instance, raised glucose is used as an indicator of diabetes, and cholesterol is used as an indicator of raised risk of heart disease and stroke. Dr. Peter J. Mazzone, a lung specialist and director of the Lung Cancer Program for the Respiratory Institute at Cleveland Clinic, says they found "patients with lung cancer have altered metabolic processes. This information could lead to the development of a diagnostic biomarker for early detection of lung cancer."
MEMBER & RESEARCH HIGHLIGHTS
Liu Named Mt. Sinai Health Care Foundation Scholar
Huiping Liu, MD, PhD, Assistant Professor of Pathology at Case Western Reserve University School of Medicine, was named a Mt. Sinai Health Care Foundation Scholar. The Mt. Sinai Health Care Foundation Scholars Program has assisted the CWRU School of Medicine in attracting young, highly promising research stars in order to build its basic science departments.
Dr. Liu came to CWRU from the University of Chicago, where she worked on microRNAs in human breast cancer in their Transitional Chicago Fellows Program. Currently, she is the primary investigator on a Case Comprehensive Cancer Center pilot genomics study on RNA sequencing of breast cancer stem cells.
MARK YOUR CALENDARS
2014 Adolescent and Young Adult Cancers Symposium
There is still time to register for the first Adolescent and Young Adult (AYA) cancer conference hosted by the Case Comprehensive Cancer Center is being held October 30-31 at the Wolstein Research Building. This collaborative symposium is organized by the Angie Fowler Adolescent & Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children's Hospital, UH Seidman Cancer Center, Case Comprehensive Cancer Center, and the Oregon Health & Science University Knight Cancer Institute. The focus of this two-day symposium is on advancement of AYA-related cancer research, including exploration of scientific, clinical and psychological considerations in adolescent and young adult cancer patients.
We are excited to feature two key speakers from University Hospitals Case Medical Center, Dr. Henry Koon, Disease Team Leader of Melanoma and Dr. Cheryl Kingsberg, Division Chief Ob/GYN Behavioral Medicine, CWRU Obstetrics and Gynecology, University Hospitals MacDonald Women's Hospital.
We hope that you will join us this year for our first AYA cancer conference, and we hope that we can help you connect to an international community of researchers and advocates for the AYA cancer community. Register today! Continuing Medical Education credits are available.
Symposium on Global Cancer Research: Call for Abstracts
The Symposium on Global Cancer Research, sponsored by the National Cancer Institute (NCI), Consortium of Universities for Global Health (CUGH) and Dana-Farber Cancer Institute, will be held March 25, 2015 at the Boston Sheraton Hotel, prior to the start of the 6th Annual CUGH Global Health Conference.
The Symposium is an annual event started in 2013 that aims to promote the exchange of scientific findings, best practices, and innovations in global cancer research. In addition, Symposium participants work to identify potential geographic and scientific areas for collaboration, and to develop strategic priorities related to cancer research focused on low- and middle-income countries (LMICs). Highly interactive discussions will cover a range of topics, foster network building, and be geared toward developing action items for advancing global cancer research priorities. The Symposium consistently draws quality senior- and junior-level professionals from multiple sectors, providing a valuable combination of experience, enthusiasm and varied perspectives to the discussions.
Call for Poster Abstracts is now open. Abstracts are due December 15, 2014. Presentation of cutting-edge research that addresses the global burden of cancer is at the heart of the Symposium. NCI invites all persons wishing to report original research, innovative projects or novel programs related to global cancer research and control to submit abstracts to be considered for posters. Abstracts will be collected through two categories:
- Scientific: original research (abstracts must include background, aims, methods, results, and significance)
- Program: innovative projects that move the field forward (abstracts must include background, purpose/goals, methods, outcomes, and next steps).
*Please note: Registration for the Symposium on Global Cancer Research is separate from registration for the 6th Annual CUGH Global Health Conference.
Limited Submission: Rita Allen Foundation Scholars Program
The Rita Allen Foundation Scholars Program provides grants to leading medical research institutions selected by the Rita Allen Foundation Scientific Advisory Committee and confirmed by the Rita Allen Foundation Board of Directors. The Scholars Program supports research scientists in the early stages of their careers. Fields of research are cancer, immunology, and neuroscience. Individuals chosen will be designated Rita Allen Foundation Scholars and the affiliated institution will receive financial support from the Rita Allen Foundation of up to $110,000 annually, for a period of up to five years.
CWRU LOI Deadline: November 17
External Application Deadline: December 12
Radiological Society of North America
The Radiological Society of North America is offering seed grants to enable all levels of investigators throughout the world in defining objectives and testing hypotheses in preparation of major grant applications to corporations, foundations, and governmental agencies. The seed data from these projects will indicate feasibility and appropriateness of the research prior to applying for funds from other agencies. Applicant must be an RSNA Member (at any level) at the time of application, and must hold a full-time faculty position in a department of radiology, radiation oncology, or nuclear medicine within an educational institution.
Deadline: January 15, 2015
Support of Case CCC Scientific Program Projects
Proposals are requested from the Case CCC Scientific Programsaddressing unique research opportunities, innovative ideas or areas identified as strategically important to the program. Proposals must be for projects that are aligned with the goals described in the Cancer Center Strategic Plan. They may build on the institutional investments in genomics and informatics, drug screening and discovery, promote the development and use of new technologies, foster new collaborations or strengthen existing research teams through the development of new research areas aligned with the scientific program strategic plan. Attention to catchment area related research is preferred. Proposals should be multi-investigator in nature, with inclusion of translational or clinical research projects.
Each program is asked to submit one response to this RFA.Program leaders must be engaged in identifying potential areas or recommending topics and proposals for the program. Proposals must be reviewed by a committee within the program that is convened specifically for this purpose before being submitted to the Cancer Center Executive Committee. The Executive Committee will make the final determination for funding after evaluating proposals and reviews. It is expected that the research projects will lead to nationally competitive grant proposals from multi-investigator teams.
Deadline for Submission to Program Leaders: November 7
Deadline for Submission of priority proposals to Executive Committee: December 15
Support of Multi-investigator Initiatives in the Case CCC
The Case CCC will provide two modes of support to new research teams that plan to submit large multi-investigator grant applications (usually non-R support mechanisms).
- Administrative support and funding for travel are available to encourage team member meetings and meetings with external advisors.
- Pilot project funding for research teams with an established track record of collaborative research is available to support key research initiatives that are necessary to generate competitive multi-investigator proposals.
Requests are competitive. The research team must demonstrate the active engagement of members, clearly articulate the significance and innovation of the project, and provide a roadmap for acquisition of external funding. Advocacy and support of the specific program leadersinteracting with the team is required. Discussion with Ruth Keri, PhD, Associate Director for Basic Research, is strongly encouraged before developing an application.
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at email@example.com.